Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.46 |
| ▸ | RAB9A | P51151 | 9/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.46 |
| ▸ | TP53 | P04637 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13763311 | 0.89 | RAB9A (0.51) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL13996002 | 0.88 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL13544354 | 0.85 | RAB9A (0.49) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL13763375 | 0.84 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL13763376 | 0.84 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL13995995 | 0.84 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL13763350 | 0.83 | SMN1; SMN2 (0.45) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL13544729 | 0.83 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL13763273 | 0.82 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL13763352 | 0.82 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576099-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | NPC1 959/4885RAB9A 2274/4885SMN1; SMN2 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.